Øyvind Sverre Bruland
Fondateur chez Artbio, Inc.
Profil
Øyvind Sverre Bruland is the founder of Algeta ASA, founded in 1997, Nordic Nanovector ASA, founded in 2009, Oncoinvent AS, founded in 2010, and Artbio, Inc., founded in 2021.
He held no titles at Algeta ASA and Nordic Nanovector ASA. At Oncoinvent AS, he held the title of Director, and at Artbio, Inc., he held the title of Chairman-Scientific Advisory Board.
Currently, he is a Professor at the University of Oslo.
Postes actifs de Øyvind Sverre Bruland
| Sociétés | Poste | Début |
|---|---|---|
| University of Oslo | Corporate Officer/Principal | - |
Artbio, Inc.
 Artbio, Inc. Hospital/Nursing ManagementHealth Services Artbio, Inc. is a company that is focused on redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building an ecosystem that maximizes their potential. Artbio is based in Cambridge, MA and has subsidiaries in Norway. The company puts the patient at the core of everything they do. The company was founded in 2021 by Emanuele Ostuni, Roy Hartvig Larsen, and Øyvind Sverre Bruland. Emanuele Ostuni has been the CEO since 2021. | Fondateur | 01/01/2021 |
Anciens postes connus de Øyvind Sverre Bruland
| Sociétés | Poste | Fin |
|---|---|---|
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Fondateur | - |
| THOR MEDICAL | Fondateur | - |
| ALGETA ASA | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Health Technology |
Artbio, Inc.
Artbio, Inc. Hospital/Nursing ManagementHealth Services Artbio, Inc. is a company that is focused on redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building an ecosystem that maximizes their potential. Artbio is based in Cambridge, MA and has subsidiaries in Norway. The company puts the patient at the core of everything they do. The company was founded in 2021 by Emanuele Ostuni, Roy Hartvig Larsen, and Øyvind Sverre Bruland. Emanuele Ostuni has been the CEO since 2021. | Health Services |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
